Amelioration of hypoxia and LPS-induced intestinal epithelial barrier dysfunction by emodin through the suppression of the NF-κB and HIF-1α signaling pathways

International Journal of Molecular Medicine

Volumn 34, Issue 6, 2014, Pages 1629-1639

  Qi, Lei ^a   Fu, Qiang ^b   Du, Chao ^c   Wu, Di ^a   Zhang, Guoqian ^d   Yuan, Bo ^c   Yan, Lina ^c  

^a TIANJIN HUANHU HOSPITAL   (China)

^b TIANJIN FOURTH CENTRAL HOSPITAL   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d FIRST TEACHING HOSPITAL OF TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cyclooxygenase 2; Emodin; Hypoxia inducible factor 1 ; Intestinal barrier dysfunction; Nuclear factor B

Indexed keywords

CLAUDIN 1; CYCLOOXYGENASE 2; EMODIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OCCLUDIN; PROTEIN ZO1; TIGHT JUNCTION PROTEIN; TRANSCRIPTION FACTOR RELA; I KAPPA B; NF-KAPPAB INHIBITOR ALPHA; OXYGEN; PROTEIN KINASE INHIBITOR;

ARTICLE; CACO 2 CELL LINE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; HYPOXIA; INTESTINE EPITHELIUM; INTESTINE EPITHELIUM CELL; MOLECULAR BIOLOGY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL HYPOXIA; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; INTESTINE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY; TIGHT JUNCTION; TIME;

BLOTTING, WESTERN; CACO-2 CELLS; CELL HYPOXIA; CLAUDIN-1; CYCLOOXYGENASE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EMODIN; EPITHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; I-KAPPA B PROTEINS; INTESTINES; LIPOPOLYSACCHARIDES; NF-KAPPA B; OCCLUDIN; OXYGEN; PERMEABILITY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TIGHT JUNCTIONS; TIME FACTORS; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84908067058     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1965     Document Type: Article

References (72)

1. Kannan KB, Colorado I, Reino D., Palange D, Lu Q, Qin X., Abungu B, Watkins A, Caputo F.J., Xu DZ, Semenza GL, Deitch EA and Feinman R: Hypoxia-inducible factor plays a gut-injurious role in intestinal ischemia reperfusion injury. Am J Physiol Gastrointest Liver Physiol 300: G853-G861, 2011.
2. Dellinger RP: Cardiovascular management of septic shock. Crit Care Med 31: 946-955, 2003.
3. Linde-Zwirble WT and Angus DC: Severe sepsis epidemiology: sampling, selection, and society. Crit Care 8: 222-226, 2004.
4. Dombrovskiy VY, Martin AA, Sunderram J and Paz HL: Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 35: 1244-1250, 2007.
5. Carrico CJ, Meakins JL, Marshall J.C., Fry D and Maier RV: Multiple-organ-failure syndrome. Arch Surg 121: 196-208, 1986.
6. Sumbayev VV, Yasinska I, Oniku A.E., Streatfield CL, Gibbs BF: Involvement of hypoxia-inducible factor-1 in the inflammatory responses of human LAD2 mast cells and basophils. PLoS One 7: e34259, 2012.
7. Cramer T, Yamanishi Y, Clausen B.E., Förster I, Pawlinski R., Mackman N, Haase VH, Jaenisch R, Corr M., Nizet V, Firestein GS, Gerber H P, Ferrara N and Johnson RS: HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 112: 645-657, 2003.
8. Harada H, Inoue M, Itasaka S., Hirota K, Morinibu A, Shinomiya K., Zeng L, Ou G, Zhu Y., Yoshimura M, McKenna WG, Muschel RJ and Hiraoka M: Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 3: 783, 2012.
9. Erratum in: Nat Commun. 2013; 4. doi:10.1038/ncomms3314.
10. Wang GL and Semenza GL: Characterization of hypoxia-inducible factor 1 and regulation of dna binding activity by hypoxia. J Biol Chem 268: 21513-21518, 1993.
11. Cao M, Wang P, Sun C., He W and Wang F: Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One 8: e61944, 2013.
12. Koury J, Deitch EA, Homma H, Abungu B., Gangurde P, Condon MR, Lu Q, Xu DZ and Feinman R: Persistent HIF-1alpha activation in gut ischemia/reperfusion injury: potential role of bacteria and lipopolysaccharide. Shock 22: 270-277, 2004.
13. Patel NJ, Zaborina O, Wu L., Wang Y, Wolfgeher DJ, Valuckaite V, Ciancio M.J., Kohler JE, Shevchenko O, Colgan SP, Chang E.B., Turner JR and Alverdy JC: Recognition of intestinal epithelial HIF-1alpha activation by Pseudomonas aeruginosa. Am J Physiol Gastrointest Liver Physiol 292: G134-G142, 2007.
14. Kelly CJ, Glover LE, Campbell E.L., Kominsky DJ, Ehrentraut SF, Bowers BE, Bayless A.J., Saeedi BJ and Colgan SP: Fundamental role for HIF-1α in constitutive expression of human β defensin-1. Mucosal Immunol 6: 1110-1118, 2013.
15. Clambey ET, McNamee EN, Westrich J.A., Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC, Stenmark KR, Colgan SP and Eltzschig HK: Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 109: E2784-E2793, 2012.
16. Kong T, Westerman KA, Faigle M, Eltzschig HK and Colgan SP: HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J 20: 2242-2250, 2006.
17. Keely S, Campbell EL, Baird A.W., Hansbro PM, Shalwitz RA, Kotsakis A, McNamee E.N., Eltzschig HK, Kominsky DJ and Colgan SP: Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis. Mucosal Immunol 7: 114-123, 2014.
18. Lee JY, Hirota SA, Glover L.E., Armstrong GD, Beck PL and MacDonald JA: Effects of nitric oxide and reactive oxygen species on HIF-1α stabilization following clostridium difficile toxin exposure of the Caco-2 epithelial cell line. Cell Physiol Biochem 32: 417-430, 2013.
19. Liu H, Li M, Wang P and Wang F: Blockade of hypoxia-inducible factor-1α by YC-1 attenuates interferon-γ and tumor necrosis factor-α-induced intestinal epithelial barrier dysfunction. Cytokine 56: 581-588, 2011.
20. Feinman R, Deitch EA, Watkins A.C., Abungu B., Colorado I, Kannan KB, Sheth S.U., Caputo FJ, Lu Q, Ramanathan M, Attan S., Badami CD, Doucet D, Barlos D, Bosch-Marce M, Semenza GL and Xu DZ: HIF-1 mediates pathogenic inflam-matory responses to intestinal ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 299: G833-G843, 2010.
21. Yang S, Yu M, Sun L., Xiao W, Yang X, Sun L., Zhang C, Ma Y, Yang H., Liu Y, Lu D, Teitelbaum DH and Yang H: Interferon-γ-induced intestinal epithelial barrier dysfunction by N F-κ B/H I F -1α pat hway. J Inter feron C ytok i ne Res 34: 195-203, 2014.
22. Peyssonnaux C, Datta V, Cramer T., Doedens A, Theodorakis EA, Gallo R.L., Hurtado-Ziola N, Nizet V and Johnson RS: HIF-1alpha expression regulates the bactericidal capacity of phagocytes. J Clin Invest 115: 1806-1815, 2005.
23. Peyssonnaux C, Cejudo-Martin P, Doedens A., Zinkernagel AS, Johnson RS and Nizet V: Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysac-charide-induced sepsis. J Immunol 178: 7516-7519, 2007.
24. Hoesel B and Schmid JA: The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 12: 86, 2013.
25. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W and Haegeman G: Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol 64: 963-970, 2002.
26. Xiao LJ, Chen YY, Lin P, Zou H.F., Lin F., Zhao LN, Li D, Guo L, Tang J.B., Zheng XL and Yu XG: Hypoxia increases CX3CR1 expression via HIF-1 and NF-κB in androgen-independent prostate cancer cells. Int J Oncol 41: 1827-1836, 2012.
27. Lau TY, Xiao J, Liong E.C., Liao L., Leung TM, Nanji AA, Fung ML and Tipoe GL: Hepatic response to chronic hypoxia in experimental rat model through HIF-1 alpha, activator protein-1 and NF-kappa B. Histol Histopathol 28: 463-471, 2013.
28. Short SS, Wang J, Castle S.L., Fernandez GE, Smiley N, Zobel M, Pontarelli E.M., Papillon SC, Grishin AV and Ford HR: Low doses of celecoxib attenuate gut barrier failure during experimental peritonitis. Lab Invest 93: 1265-1275, 2013.
29. Fitzpatrick SF, Tambuwala MM, Bruning U, Schaible B., Scholz CC, Byrne A, O'Connor A, Gallagher WM, Lenihan C.R., Garvey JF, Howell K, Fallon PG, Cummins EP and Taylor CT: An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia. J Immunol 186: 1091-1096, 2011.
30. Cook-Johnson R.J., Demasi M, Cleland L.G., Gamble JR, Saint DA and James MJ: Endothelial cell COX-2 expression and activity in hypoxia. Biochim Biophys Acta 1761: 1443-1449, 2006.
31. Schmedtje JF J.r., Ji YS, Liu W.L., DuBois RN and Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997.
32. Lukiw WJ, Ottlecz A, Lambrou G., Grueninger M, Finley J, Thompson HW and Bazan NG: Coordinate activation of HIF-1 and NF-κB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Invest Ophthalmol Vis Sci 44: 4163-4170, 2003.
33. Shi YQ, Fukai T, Sakagami H., Kuroda J, Miyaoka R, Tamura M., Yoshida N and Nomura T: Cytotoxic and DNA damage-inducing activities of low molecular weight phenols from rhubarb. Anticancer Res 21: 2847-2853, 2001.
34. Wu L, Cai B, Zheng S., Liu X, Cai H and Li H: Effect of emodin on endoplasmic reticulum stress in rats with severe acute pancreatitis. Inflammation 36: 1020-1029, 2013.
35. Cha TL, Chuang MJ, Tang S.H., Wu ST, Sun KH, Chen TT, Sun G.H., Chang SY, Yu CP, Ho JY, Liu S.Y., Huang SM and Yu DS: Emodin modulates epigenetic modifications and suppresses bladder carcinoma cell growth. Mol Carcinog: Sep 20, 2013 (Epub ahead of print).
36. Hwang JK, Noh EM, Moon S.J., Kim JM, Kwon KB, Park BH, You Y.O., Hwang BM, Kim HJ, Kim BS, Lee S.J., Kim JS and Lee YR: Emodin suppresses inflammatory responses and joint destruction in collagen-induced arthritic mice. Rheumatology (Oxford) 52: 1583-1591, 2013.
37. Chen D, Xiong Y, Wang L., Lv B and Lin Y: Characteristics of emodin on modulating the contractility of jejunal smooth muscle. Can J Physiol Pharmacol 90: 455-462, 2012.
38. Cummins EP, Doherty GA and Taylor CT: Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest 93: 378-383, 2013.
39. Xiao WD, Chen W, Sun L.H., Wang WS, Zhou SW and Yang H: The protective effect of enteric glial cells on intestinal epithelial barrier function is enhanced by inhibiting inducible nitric oxide synthase activity under lipopolysaccharide stimulation. Mol Cell Neurosci 46: 527-534, 2011.
40. Tambuwala MM, Cummins EP, Lenihan C.R., Kiss J., Stauch M, Scholz CC, Fraisl P, Lasitschka F., Mollenhauer M, Saunders SP, Maxwell P.H., Carmeliet P., Fallon PG, Schneider M and Taylor CT: Loss of prolyl hydroxylase-1 protects against colitis through reduced epithelial cell apoptosis and increased barrier function. Gastroenterology 139: 2093-2101, 2010.
41. Wang P, Qi H, Sun C., He W, Chen G, Li L and Wang F: Overexpression of hypoxia-inducible factor-1α exacerbates endothelial barrier dysfunction induced by hypoxia. Cell Physiol Biochem 32: 859-870, 2013.
42. Dehne N, Tausendschon M, Essler S., Geis T, Schmid T and Brune B: IL-4 reduces the proangiogenic capacity of macrophages by down-regulating HIF-1α translation. J Leukoc Biol 95: 129-137, 2014.
43. Westra J, Brouwer E, van Roosmalen I A, Doornbos-van der Meer B, van Leeuwen MA, Posthumus MD and Kallenberg CG: Expression and regulation of HIF-1alpha in macrophages under inflammatory conditions; significant reduction of VEGF by CaMKII inhibitor. BMC Musculoskelet Disord 11: 61-72, 2010.
44. Clark JA and Coopersmith CM: Intestinal crosstalk: a new paradigm for understanding the gut as the 'motor' of critical illness. Shock 28: 384-393, 2007.
45. Suzuki T: Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 70: 631-659, 2013.
46. Shen L, Weber CR, Raleigh D.R., Yu D and Turner JR: Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 73: 283-309, 2011.
47. Turner JR: Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799-809, 2009.
48. Tozzi MG, Pesi R and Allegrini S: On the physiological role of cytosolic 5'-nucleotidase II (cN-II): pathological and therapeutical implications. Curr Med Chem 20: 4285-4291, 2013.
49. Ulluwishewa D, Anderson RC, McNabb W.C., Moughan PJ, Wells JM and Roy NC: Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 141: 769-776, 2011.
50. Ratcliffe PJ: HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 117: 862-865, 2007.
51. Majmundar AJ, Wong WJ and Simon MC: Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 40: 294-309 2010.
52. Glover LE, Bowers BE, Saeedi B, Ehrentraut S.F., Campbell EL, Bayless AJ, Dobrinskikh E, Kendrick A.A., Kelly CJ, Burgess A, Miller L, Kominsky D.J., Jedlicka P and Colgan SP: Control of creatine metabolism by HIF is an endogenous mechanism of barrier regulation in colitis. Proc Natl Acad Sci USA 110: 19820-19825, 2013.
53. Glover LE, Irizarry K, Scully M., Campbell EL, Bowers BE, Aherne CM, Kominsky D.J., MacManus CF and Colgan SP: IFN-γ attenuates hypoxia-inducible factor (HIF) activity in intestinal epithelial cells through transcriptional repression of HIF-1β. J Immunol 186: 1790-1798, 2011.
54. Kang DW, Park MK, Oh H.J., Lee DG, Park SH, Choi KY, Cho ML and Min do S: Phospholipase D1 has a pivotal role in interleukin-1β-driven chronic autoimmune arthritis through regulation of NF-κB, hypoxia-inducible factor 1α, and FoxO3a. Mol Cell Biol 33: 2760-2772, 2013.
55. Pouysségur J and Mechta-Grigoriou F: Redox regulation of the hypoxia-inducible factor. Biol Chem 387: 1337-1346, 2006.
56. Frede S, Stockmann C, Freitag P and Fandrey J: Bacterial lipo-polysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J 396: 517-527, 2006.
57. Walmsley SR, Print C, Farahi N., Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A., Condliffe AM, Cowburn AS, Johnson N and Chilvers ER: Hypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity. J Exp Med 201: 105-115, 2005.
58. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E., Mager A, Morote-Garcia JC, Unertl K and Eltzschig HK: Hypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia. Nat Immunol 10: 195-202, 2009.
59. Eckle T, Faigle M, Grenz A., Laucher S, Thompson LF and Eltzschig HK: A2B adenosine receptor dampens hypoxia-induced vascular leak. Blood 111: 2024-2035, 2008.
60. Eltzschig HK, Abdulla P, Hoffman E., Hamilton KE, Daniels D, Schönfeld C, Löffler M, Reyes G., Duszenko M, Karhausen J, Robinson A., Westerman KA, Coe IR and Colgan SP: HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 202: 1493-1505, 2005.
61. Hartmann G, Tschöp M, Fischer R., Bidlingmaier C, Riepl R, Tschöp K, Hautmann H., Endres S and Toepfer M: High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine 12: 246-252, 2000.
62. Park SW, Kim M, Brown K.M., D'Agati VD and Lee HT: Paneth cell-derived interleukin-17A causes multiorgan dysfunction after hepatic ischemia and reperfusion injury. Hepatology 53: 1662-1675, 2011.
63. Kim M, Kim M, Park S.W., Pitson SM and Lee HT: Isoflurane protects human kidney proximal tubule cells against necrosis via sphingosine kinase and sphingosine-1-phosphate generation. Am J Nephrol 31: 353-362, 2010.
64. Hart ML, Jacobi B, Schittenhelm J., Henn M and Eltzschig HK: Cutting Edge: A2B adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury. J Immunol 182: 3965-3968, 2009.
65. Karhausen J, Haase VH and Colgan SP: Inflammatory hypoxia: role of hypoxia-inducible factor. Cell Cycle 4:256-258, 2005.
66. Paiotti A.P., Marchi P, Miszputen S.J., Oshima CT, Franco M and Ribeiro DA: The role of nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors on experimental colitis. In Vivo 26: 381-393 2012.
67. Paiotti AP, Ribeiro DA, Silva R.M., Marchi P., Oshima CT, Neto RA, Miszputen SJ and Franco M: Effect of COX-2 inhibitor lumi-racoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats. J Mol Histol 43: 307-317, 2012.
68. Muthusamy A, Lin CM, Shanmugam S, Lindner H.M., Abcouwer SF and Antonetti DA: Ischemia-reperfusion injury induces occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner. J Cereb Blood Flow Metab 34: 522-531, 2014.
69. Liu H, Wang P, Cao M., Li M and Wang F: Protective role of oligomycin against intestinal epithelial barrier dysfunction caused by IFN-γ and TNF-α. Cell Physiol Biochem 29: 799-808, 2012.
70. Qi H, Wang P, Liu C., Li M, Wang S, Huang Y and Wang F: Involvement of HIF-1α in MLCK-dependent endothelial barrier dysfunction in hypoxia. Cell Physiol Biochem 27: 251-262, 2011.
71. 4. Molecules 18: 11842-11858, 2013.
72. Kim JR, Oh DR, Cha M.H., Pyo BS, Rhee JH, Choy HE, Oh WK and Kim YR: Protective effect of polygoni cuspidati radix and emodin on Vibrio vulnificus cytotoxicity and infection. J Microbiol 46: 737-743, 2008.